140 related articles for article (PubMed ID: 17976974)
1. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
Kim MK; Cho KJ; Kwon GY; Park SI; Kim YH; Kim JH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Kim SB
Eur J Cancer; 2008 Jan; 44(1):54-60. PubMed ID: 17976974
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
3. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy.
Kim MK; Cho KJ; Kwon GY; Park SI; Kim YH; Kim JH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Kim SB
Clin Cancer Res; 2008 Jul; 14(13):4225-31. PubMed ID: 18594004
[TBL] [Abstract][Full Text] [Related]
4. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
Joshi MB; Shirota Y; Danenberg KD; Conlon DH; Salonga DS; Herndon JE; Danenberg PV; Harpole DH
Clin Cancer Res; 2005 Mar; 11(6):2215-21. PubMed ID: 15788669
[TBL] [Abstract][Full Text] [Related]
5. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
7. High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients.
Langer R; Ott K; Feith M; Lordick F; Specht K; Becker K; Hofler H
J Surg Oncol; 2010 Oct; 102(5):503-8. PubMed ID: 20589706
[TBL] [Abstract][Full Text] [Related]
8. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
Ronchi CL; Sbiera S; Kraus L; Wortmann S; Johanssen S; Adam P; Willenberg HS; Hahner S; Allolio B; Fassnacht M
Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
[TBL] [Abstract][Full Text] [Related]
9. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.
Lee SH; Noh KB; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kim CH; Kang KH; In KH
Lung Cancer; 2013 Jul; 81(1):102-8. PubMed ID: 23523421
[TBL] [Abstract][Full Text] [Related]
10. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
Kawashima A; Nakayama M; Kakuta Y; Abe T; Hatano K; Mukai M; Nagahara A; Nakai Y; Oka D; Takayama H; Yoshioka T; Hoshida Y; Itatani H; Nishimura K; Nonomura N
Clin Cancer Res; 2011 Apr; 17(8):2561-9. PubMed ID: 21177407
[TBL] [Abstract][Full Text] [Related]
11. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Lee S; Park YH; Kim KH; Cho EY; Ahn YC; Kim K; Shim YM; Ahn JS; Park K; Im YH
Br J Cancer; 2010 Sep; 103(6):845-51. PubMed ID: 20700125
[TBL] [Abstract][Full Text] [Related]
12. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.
Harpole DH; Moore MB; Herndon JE; Aloia T; D'Amico TA; Sporn T; Parr A; Linoila I; Allegra C
Clin Cancer Res; 2001 Mar; 7(3):562-9. PubMed ID: 11297249
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of p53 and 14-3-3sigma for the effect of chemoradiation therapy on esophageal squamous cell carcinoma.
Okumura H; Natsugoe S; Matsumoto M; Yokomakura N; Uchikado Y; Takatori H; Ishigami S; Takao S; Aikou T
J Surg Oncol; 2005 Jul; 91(1):84-9. PubMed ID: 15999354
[TBL] [Abstract][Full Text] [Related]
15. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
[TBL] [Abstract][Full Text] [Related]
16. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus.
Ariga H; Nemoto K; Miyazaki S; Yoshioka T; Ogawa Y; Sakayauchi T; Jingu K; Miyata G; Onodera K; Ichikawa H; Kamei T; Kato S; Ishioka C; Satomi S; Yamada S
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):348-56. PubMed ID: 19735862
[TBL] [Abstract][Full Text] [Related]
17. [ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma].
Sobajima J; Haga N; Kumamoto K; Ishibashi K; Ishida H
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2394-6. PubMed ID: 21224584
[TBL] [Abstract][Full Text] [Related]
18. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.
Kim KH; Kwon HC; Oh SY; Kim SH; Lee S; Kwon KA; Jang JS; Kim MC; Kim SJ; Kim HJ
Biomarkers; 2011 Feb; 16(1):74-82. PubMed ID: 21133646
[TBL] [Abstract][Full Text] [Related]
20. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer.
Miyoshi N; Yano M; Takachi K; Kishi K; Noura S; Eguchi H; Yamada T; Miyashiro I; Ohue M; Ohigashi H; Sasaki Y; Ishikawa O; Doki Y; Imaoka S
J Surg Oncol; 2009 Apr; 99(5):302-6. PubMed ID: 19170110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
